Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-amino-5-chloro-n-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide
2. Motegrity
3. Prucalopride
4. R 093877
5. R093877
6. Resolor
7. Resotran
8. Resotrans
1. 179474-85-2
2. Resolor
3. Prucalopride Succinat
4. Prucalopride (succinate)
5. R-108512
6. Butanedioic Acid 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide
7. Prucalopride Succinate [usan]
8. Prucalopride (as Succinate)
9. 4v2g75e1ck
10. 179474-85-2 (succinate)
11. 4-amino-5-chloro-n-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide Succinate
12. Butanedioic Acid, Compd. With 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1)
13. Butanedioic Acid, Compd. With 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide (1:1)
14. Prucalopride Succinate (usan)
15. Resotran
16. 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;butanedioic Acid
17. Resolor (tn)
18. Unii-4v2g75e1ck
19. R-93877
20. Resolor Succinate
21. Motegrity (tn)
22. Prucalopridesuccinate
23. R 108512
24. Mls006011219
25. Schembl1230437
26. Chembl2105748
27. Dtxsid701027749
28. Hms3652b21
29. Hms3885j13
30. Bcp09320
31. Mfcd00948731
32. S4247
33. Akos015994741
34. Prucalopride Succinate [mart.]
35. Ccg-269590
36. Cs-3907
37. Ks-1283
38. Prucalopride Succinate [who-dd]
39. 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide,butanedioic Acid
40. Ac-29960
41. Butanedioic Acid 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarb
42. Hy-12694
43. Smr004702981
44. Db-065276
45. Prucalopride Succinate [orange Book]
46. Ft-0745512
47. Sw219198-1
48. D10152
49. A812449
50. J-519956
51. Q27260539
52. B0084-470898
| Molecular Weight | 486.0 g/mol |
|---|---|
| Molecular Formula | C22H32ClN3O7 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 485.1928781 g/mol |
| Monoisotopic Mass | 485.1928781 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 538 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
Laxatives
Agents that produce a soft formed stool, and relax and loosen the bowels, typically used over a protracted period, to relieve CONSTIPATION. (See all compounds classified as Laxatives.)
Serotonin 5-HT4 Receptor Agonists
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT4 RECEPTORS. (See all compounds classified as Serotonin 5-HT4 Receptor Agonists.)
A06AX05
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Sweden
Brand Name : Resolor
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 1 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Resolor
Dosage Form : FILMDRAGERAD TABLETT
Dosage Strength : 2 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 1 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 1 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 1 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Resolor
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 2 mg
Packaging : Calendar Gasket
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Resolor
Dosage Form : Filmtabl
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Resolor
Dosage Form : Filmtabl
Dosage Strength : 2mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Prucalopride Succinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Prucalopride Succinate manufacturer or Prucalopride Succinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prucalopride Succinate manufacturer or Prucalopride Succinate supplier.
PharmaCompass also assists you with knowing the Prucalopride Succinate API Price utilized in the formulation of products. Prucalopride Succinate API Price is not always fixed or binding as the Prucalopride Succinate Price is obtained through a variety of data sources. The Prucalopride Succinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Prucalopride Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prucalopride Succinate, including repackagers and relabelers. The FDA regulates Prucalopride Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prucalopride Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Prucalopride Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Prucalopride Succinate supplier is an individual or a company that provides Prucalopride Succinate active pharmaceutical ingredient (API) or Prucalopride Succinate finished formulations upon request. The Prucalopride Succinate suppliers may include Prucalopride Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Prucalopride Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Prucalopride Succinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Prucalopride Succinate active pharmaceutical ingredient (API) in detail. Different forms of Prucalopride Succinate DMFs exist exist since differing nations have different regulations, such as Prucalopride Succinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Prucalopride Succinate DMF submitted to regulatory agencies in the US is known as a USDMF. Prucalopride Succinate USDMF includes data on Prucalopride Succinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prucalopride Succinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Prucalopride Succinate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Prucalopride Succinate Drug Master File in Korea (Prucalopride Succinate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Prucalopride Succinate. The MFDS reviews the Prucalopride Succinate KDMF as part of the drug registration process and uses the information provided in the Prucalopride Succinate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Prucalopride Succinate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Prucalopride Succinate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Prucalopride Succinate suppliers with KDMF on PharmaCompass.
A Prucalopride Succinate written confirmation (Prucalopride Succinate WC) is an official document issued by a regulatory agency to a Prucalopride Succinate manufacturer, verifying that the manufacturing facility of a Prucalopride Succinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Prucalopride Succinate APIs or Prucalopride Succinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Prucalopride Succinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Prucalopride Succinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Prucalopride Succinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Prucalopride Succinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Prucalopride Succinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Prucalopride Succinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Prucalopride Succinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Prucalopride Succinate suppliers with NDC on PharmaCompass.
Prucalopride Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Prucalopride Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Prucalopride Succinate GMP manufacturer or Prucalopride Succinate GMP API supplier for your needs.
A Prucalopride Succinate CoA (Certificate of Analysis) is a formal document that attests to Prucalopride Succinate's compliance with Prucalopride Succinate specifications and serves as a tool for batch-level quality control.
Prucalopride Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Prucalopride Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Prucalopride Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Prucalopride Succinate EP), Prucalopride Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prucalopride Succinate USP).
